Ischemic stroke is a cerebrovascular disease normally caused by interrupted blood supply to
the brain. Ischemia would initiate the cascade reaction consisted of multiple biochemical …

Ischemic stroke leads to high disability and mortality. The limited delivery efficiency of most
therapeutic substances is a major challenge for effective treatment of ischemic stroke …

Ischemic stroke is a vascular central nervous system (CNS) disease that leads a disability
and death. Thrombolysis and neuroprotection are the primary treatment strategies of …

Arginine‐glycine‐aspartic acid (RGD) peptide family is known as the most prominent ligand
for extracellular domain of integrin receptors. Specific expression of these receptors in …

Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its
short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to …

Thrombosis, a critical event in blood vessels, not only is associated with myocardial
infarction and stroke, but also accounts for considerable morbidity and mortality …

Antithrombotic therapy is confronted with short half-lives of thrombolytic agents and high
bleeding risks. Challenges remain in the development of drug delivery systems for thorough …

Tissue plasminogen activator (tPA) is the sole approved therapeutic molecule for the
treatment of acute ischemic stroke. Yet, only a small percentage of patients could benefit …

Thrombosis is a life‐threatening pathological condition in which blood clots form in blood
vessels, obstructing or interfering with blood flow. Thrombolytic agents (TAs) are enzymes …

Therapeutic enzymes are one of the most promising applications of this century in the field of
pharmaceutics. Biocatalyst properties can be improved by enzyme immobilization on nano …